Related Experiment Videos
Olanzapine in treatment-resistant bipolar disorder
S L McElroy1, M Frye, K Denicoff
1Stanley Foundation Bipolar Treatment Outcome Network, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267, USA.
Journal of Affective Disorders
|June 3, 1998
Summary
Olanzapine showed potential in treating bipolar I disorder when standard treatments failed. This study found 57% of patients improved, with generally good tolerability, suggesting further research is warranted.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Bipolar I disorder often requires multiple treatment strategies.
- Some patients show inadequate response to standard mood stabilizers.
Purpose of the Study:
- To evaluate the efficacy and tolerability of olanzapine.
- To assess olanzapine's response in patients with treatment-resistant bipolar I disorder.
Main Methods:
- Open-label trial involving 14 patients with bipolar I disorder.
- Patients received olanzapine treatment for persistent affective symptoms.
- Response assessed using the modified Clinical Global Impression Scale for Bipolar Disorder (CGI-BP).
Main Results:
- 8 out of 14 patients (57%) showed significant improvement.
- Olanzapine was administered at an average dosage of 14.1 mg/day.
- Common side effects included sedation, dry mouth, and weight gain.
Conclusions:
- Olanzapine may offer antimanic and mood-stabilizing benefits.
- The drug was generally well-tolerated in this patient group.
- Further controlled studies are recommended to confirm these findings.